Investigate the role of B cell in response to anti-PD1 + anti-CTLA in hepatocellular carcinoma
RNA-seq (gene expression) · mouse · 21 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 21 samples: 21 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: Long-term efficacy and biomarker explorationJournal of hepatology · 2026
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE272309_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1136401 and SRA study SRP520080. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 21 sample titles: 21 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8398230 WT + Isotype (1)
- GSM8398231 WT + Isotype (2)
- GSM8398232 WT + Isotype (3)
- GSM8398233 WT + Isotype (4)
- GSM8398234 WT + Isotype (5)
- GSM8398235 WT + anti-PD1 plus anti-CTLA4 (1)
- GSM8398236 WT + anti-PD1 plus anti-CTLA4 (2)
- GSM8398237 WT + anti-PD1 plus anti-CTLA4 (3)
- GSM8398238 WT + anti-PD1 plus anti-CTLA4 (4)
- GSM8398239 WT + anti-PD1 plus anti-CTLA4 (5)
- GSM8398240 B-cell depletion + Isotype (1)
- GSM8398241 B-cell depletion + Isotype (2)
- GSM8398242 B-cell depletion + Isotype (3)
- GSM8398243 B-cell depletion + Isotype (4)
- GSM8398244 B-cell depletion + Isotype (5)
- GSM8398245 B-cell depletion + Isotype (6)
- GSM8398246 B-cell depletion + anti-PD1 plus anti-CTLA4 (1)
- GSM8398247 B-cell depletion + anti-PD1 plus anti-CTLA4 (2)
- GSM8398248 B-cell depletion + anti-PD1 plus anti-CTLA4 (3)
- GSM8398249 B-cell depletion + anti-PD1 plus anti-CTLA4 (4)
- GSM8398250 B-cell depletion + anti-PD1 plus anti-CTLA4 (5)
- GSE311831 Pertussis toxin-induced lymphocytosis enhances anti-tumor immune environments and improves the anti-PD1 treatment response in a squamous cell carcinoma model. 24 samples shares anti-pd1
- GSE248155 Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma 31 samples shares anti-pd1
- GSE248154 Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma [4NQO_model] 19 samples shares anti-pd1
- GSE248153 Effect of regorafenib, anti-PD1, and anti-CD40 agonist in Head and Neck Squamous Cell Carcinoma [HNSCC_model] 12 samples shares anti-pd1
- GSE231357 Syndecan-1 inhibition promotes anti-tumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy 14 samples shares anti-pd1
- GSE231355 Syndecan-1 inhibition promotes anti-tumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy [kdSdc1_RNAseq] 12 samples shares anti-pd1
- GSE254619 Syndecan-1 inhibition promotes anti-tumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy (kdSdc1 and mutant) 10 samples shares anti-pd1
- GSE240840 Tumor-associated neutrophils attenuate the immuno-sensitivity of hepatocellular carcinoma and curtail immunotherapy response 23 samples shares hepatocellular
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.